Breast Cancer Heterogeneity in Primary and Metastatic Disease

2019 ◽  
pp. 75-104 ◽  
Author(s):  
Lauren Kalinowski ◽  
Jodi M. Saunus ◽  
Amy E. McCart Reed ◽  
Sunil R. Lakhani
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Cancer Heterogeneity

Breast Cancer Heterogeneity in Primary and Metastatic Disease

2012 ◽  
pp. 65-95 ◽  
Author(s):  
Jodi M. Saunus ◽  
Amy McCart-Reed ◽  
Majid Momeny ◽  
Margaret Cummings ◽  
Sunil R. Lakhani
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Cancer Heterogeneity

scholarly journals Breast Cancer Cell Re-Dissemination from Lung Metastases—A Mechanism for Enhancing Metastatic Burden

2021 ◽  
Vol 10 (11) ◽  
pp. 2340
Author(s):  
Lucia Borriello ◽  
John Condeelis ◽  
David Entenberg ◽  
Maja H. Oktay
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Metastatic Disease ◽  
Breast Cancer Cells ◽  
Lung Metastases ◽  
Primary Tumors ◽  
Metastatic Burden ◽  
First Time ◽  
Do So

Although metastatic disease is the primary cause of mortality in cancer patients, the mechanisms leading to overwhelming metastatic burden are still incompletely understood. Metastases are the endpoint of a series of multi-step events involving cancer cell intravasation, dissemination to distant organs, and outgrowth to metastatic colonies. Here we show, for the first-time, that breast cancer cells do not solely disseminate to distant organs from primary tumors and metastatic nodules in the lymph nodes, but also do so from lung metastases. Thus, our findings indicate that metastatic dissemination could continue even after the removal of the primary tumor. Provided that the re-disseminated cancer cells initiate growth upon arrival to distant sites, cancer cell re-dissemination from metastatic foci could be one of the crucial mechanisms leading to overt metastases and patient demise. Therefore, the development of new therapeutic strategies to block cancer cell re-dissemination would be crucial to improving survival of patients with metastatic disease.

scholarly journals EphA2 is a Clinically Relevant Target for Breast Cancer Bone Metastatic Disease

JBMR Plus ◽  
2021 ◽  
Author(s):  
David B. Vaught ◽  
Alyssa R. Merkel ◽  
Conor C. Lynch ◽  
James Edwards ◽  
Mohammed Noor Tantawy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease

scholarly journals Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

2015 ◽  
Vol 7 (8) ◽  
pp. 1034-1047 ◽  
Author(s):  
Eleonor Olsson ◽  
Christof Winter ◽  
Anthony George ◽  
Yilun Chen ◽  
Jillian Howlin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Primary Breast Cancer ◽  
Circulating Tumor Dna ◽  
Occult Metastatic Disease ◽  
Tumor Dna

scholarly journals A Case of Recurrent Breast Cancer with Solitary Metastasis to the Urinary Bladder

2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
Carsten Nieder ◽  
Adam Pawinski
Keyword(s):  
Breast Cancer ◽  
Urinary Bladder ◽  
Cancer Progression ◽  
Metastatic Disease ◽  
Lobular Carcinoma ◽  
Palliative Radiotherapy ◽  
Life Time ◽  
Recurrent Breast Cancer ◽  
Endocrine Treatment ◽  
Metastatic Recurrence

Elderly patients with breast cancer often present with symptomatic, locoregionally advanced rather than screening-detected disease, thereby increasing the risk of metastatic recurrence during their remaining life time. Typical sites of metastases include lungs, bones, liver, and brain. Here we present a patient who developed a solitary urinary bladder metastasis five years after primary diagnosis of stage T4 N0 estrogen receptor-positive lobular carcinoma, while on continued adjuvant endocrine treatment (91 years of age). Anemia and increased serum creatinine resulting from hydronephrosis led to diagnosis of metastatic disease, which was confirmed by transurethral resection. The patient responded clinically to palliative radiotherapy and a different type of endocrine therapy. One year after diagnosis of metastatic disease, she died without signs of cancer progression.

Screening for metastatic disease in newly diagnosed breast cancer patients

2008 ◽  
Vol 6 (7) ◽  
pp. 61
Author(s):  
E. Una ◽  
M.J. Borau ◽  
J. Nieto ◽  
A. De la Torre ◽  
G. Fernandez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Newly Diagnosed ◽  
Breast Cancer Patients

Prognostic subset of metastatic and non-metastatic luminal B breast cancer (LBBC) subtype based on Ki67 index.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12570-e12570
Author(s):  
Lalnun Puii ◽  
Lalram Sangi ◽  
Hrishi Varayathu ◽  
Samuel Luke Koramati ◽  
Beulah Elsa Thomas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Ki67 Index ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Her2 Positive ◽  
Ki 67 ◽  
Luminal B ◽  
Therapeutic Implications ◽  
Significant Difference

e12570 Background: Gene expression profiling for breast cancer has classified ER positive subtype into luminal A and luminal B. Luminal B breast cancer (LBBC) have a higher proliferation and poorer prognosis than luminal A tumors. Ki-67 index is the commonly used proliferation marker in breast cancer; however Ki67 expression can also be used to identify a subset of patients among LB with a favorable prognosis. This study attempts to verify this subset of LBBC patients based on DFS and PFS in non-metastatic and metastatic patients respectively. Methods: We retrospectively analyzed 80 IDC breast cancer patients diagnosed in 2013-2016 with complete follow-up till January-2021. We defined LBBC as ER+, PR+ or PR- , HER2+ or HER2- with a Ki67 index >20%. PFS was considered as the endpoint in patients presenting with metastatic disease whereas DFS was used in non-metastatic disease. The cut-off for ki67 was calculated using an X-tile plot (version 3.6.1, Yale University) by dividing Ki67 data into two populations: low and high, with randomized 1:1 “training” and “validation” cohorts. Results: Median age was 51.5 years. 18.7% (n=15) presented with metastasis at the time of diagnosis and their overall median PFS was found to be 25.8 months. The incidence of HER2 positive LBBC was found to be 15% (n=12) and none of them were found to be presented with metastasis. Survival and frequency of various sub groups in our study are enlisted in the given table. We estimated a Ki67 cut-off of 30% in patients with upfront metastatic disease and PFS was found to be higher in <30% compared to a Ki67 index >30% (38.9 months vs 19.7 months, p-0.002). Overall median DFS was not achieved in non-metastatic group (Mean DFS: 64.7 months) where as a statistically significant difference was observed in the survival of HER2 positive (median DFS: 53.5 months, mean DFS: 50.9) than HER2 negative patients (median DFS not achieved, mean: 66.97 months) ( p-0.021). We obtained a Ki67 cut-off of 32% in non- metastatic group and mean DFS was found to be higher in Ki67<32% (69 months) compared to Ki67>32% (61.4 months), however it failed to exhibit a statistically significant relationship ( p-0.373). Conclusions: Our study indicates that a subset of patients exists within metastatic and non-metastatic LBBC with differing prognosis based on Ki67. Larger studies are further required to confirm the findings and therapeutic implications.[Table: see text]

Final report of Breast Cancer Care Registry at the Kenyatta National Hospital, Nairobi.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12552-e12552
Author(s):  
Nicholas Anthony Othieno-Abinya ◽  
Alice Musibi ◽  
Catherine Nyongesa ◽  
Benjamin Njihia ◽  
Andrew Gachii ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Ductal Carcinoma ◽  
Clinical Care ◽  
Significant Proportion ◽  
Relative Survival ◽  
Final Report ◽  
Early Disease ◽  
National Hospital ◽  
Kenyatta National Hospital

e12552 Background: Breast cancer is the commonest cancer among women in Kenya. We wanted to examine breast cancer seen at the Kenyatta National Hospital in relation to local factors that influence prognosis and quality of life, local variations in treatment and outcomes; describe the clinical care patterns, monitor the safety of the therapies provided to patients in a routine clinic setting. Methods: A prospective study of patients with breast cancer between 11.08.2011 and 11.09.2014 inclusive. Data included demographic details, diagnostic and staging procedures, stage, treatment and outcome. Estimates of relative survival used period approach. hi-square tests and analysis of variance (ANOVA) were utilised to make comparisons. Cross sectional data are presented in proportions, means and medians. Results: Four hundred patients were included, age range 20 to 83, median 49 years. Out 312, 65 (20.8%) were obese. Eight of 397 (2%) were smokers and 22(5.5%) took alcohol. Early disease was diagnosed in 269 out of 354 (76%) and metastatic disease in 85(24%). Breast lump presented in 388 out of 400 (97%), breast pain in 104 out of 388 (26.8%). Fifteen of 394 (3.8%) had second breast cancer, 4 (1%) had had ovarian cancer and 9 (2.3%) had had had other malignancy. History of breast cancer in first and second-degree relative was elicited in 41 out of 394 (10.4%). Ductal carcinoma NOS was commonest in 343 (88.2%), lobular carcinoma in 9(2.5%). Cases by T stage were T1 - 25(7.2%), T2 -130(37.4%), T3 - 96(27.6%), T4 - 87(25%). Of 322 cases, 187(58.1%) were ER positive and 175 (54.4%) PR positive. Her2 positive cases were 78 out of 322 (24.2%). Neo adjuvant and adjuvant chemotherapy mainly consisted of combinations of cyclophosphamide and doxorubicin [AC] +/- a taxane[AC→T] ( mainly by medical oncologists) or AC+ 5-FU [CAF] (mainly by clinical oncologists). Of 305 cases 272 (89.2%) completed adjuvant therapy, 8(2.6%) died during treatment. Median overall survival was 57.1 months (95% CI; 55.6 to 59.5 months). For metastatic disease, median PFS was worse for patients < 40 years. Conclusions: Pathology and biology mirrored global situation, over 75% of patients had non metastatic disease. A significant proportion of early disease patients did not complete treatment.

Sign in / Sign up

Export Citation Format

Share Document